A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Richard Scranton, MD, MPH
Chief Medical Officer
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Collaborative Neuroscience Research, Llc
Long Beach, California, United States
- Atlanta Center for Medical Research
Atlanta, Georgia, United States
- Hassman Research Institute
Marlton, New Jersey, United States
- Community Clinical Research, Inc
Austin, Texas, United States
- Pillar Clinical Research, Llc
Richardson, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Aug 2020
- Primary completion
- 22 Dec 2020
- Completion
- 22 Dec 2020
- Last update posted
- 8 Feb 2023
- Registered enrollment
- 34
- Registry id
- NCT04567524
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.